...
首页> 外文期刊>JMIR Research Protocols >Treatment of Basal Cell Carcinoma Using a One-Stop-Shop With Reflectance Confocal Microscopy: Study Design and Protocol of a Randomized Controlled Multicenter Trial
【24h】

Treatment of Basal Cell Carcinoma Using a One-Stop-Shop With Reflectance Confocal Microscopy: Study Design and Protocol of a Randomized Controlled Multicenter Trial

机译:一站式反射共聚焦显微镜治疗基底细胞癌:随机对照多中心试验的研究设计和方案

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Basal cell carcinoma (BCC) is the most common cancer diagnosed in white populations worldwide. The rising incidence of BCC is becoming a major worldwide public health problem. Therefore, there is a need for more efficient management. Objective The aim of this research is to assess the efficacy and safety of a one-stop-shop (OSS) concept, using real-time in vivo reflectance confocal microscopy (RCM) (Vivascope 1500; Lucid Technologies, Henrietta, NY, USA) as a diagnostic tool, prior to surgical management of new primary BCCs. Methods This is a prospective non-inferiority multi-center RCT designed to compare the “OSS concept using RCM” to current standards of care in diagnosing and treating clinically suspected BCC. Patients ≥ 18 years attending our outpatient clinic at the Department of Dermatology, Academic Medical Center, University of Amsterdam, and the Department of Dermatology, the Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital (Amsterdam, The Netherlands) with a clinically suspected new primary BCC lesion will be considered for enrollment using predefined inclusion and exclusion criteria, and will be randomly allocated to the experimental or control group. The main outcome parameter is the assessment of incomplete surgical excision margins on the final pathology report of confirmed BCC lesions (either by punch biopsy or RCM imaging). Other outcome measures include diagnostic accuracy (sensitivity and specificity) of RCM for diagnosing BCC and dividing between subtypes, and throughput time. Patient satisfaction data will be collected postoperatively after 3 months during routine follow-up. Results This research is investigator-initiated and received ethics approval. Patient recruitment started in February 2015, and we expect all study-related activities to be completed by fall 2015. Conclusions This RCT is the first to examine an OSS concept using RCM for diagnosing and treating clinically suspected BCC lesions. Results of this research are expected to have applications in evidence-based practice for the increasing number of patients suffering from BCC and possibly lead to a more efficient disease management strategy. Trial Registration ClinicalTrials.gov: NCT02285790; https://clinicaltrial.gov/ct2/show/NCT02285790 (Archived by WebCite at http://www.webcitation.org/6b2LfDKWu).
机译:背景基底细胞癌(BCC)是全世界白人中最常见的癌症。 BCC发病率的上升正在成为全球主要的公共卫生问题。因此,需要更有效的管理。目的本研究的目的是使用实时体内反射共聚焦显微镜(RCM)评估一站式(OSS)概念的有效性和安全性(Vivascope 1500; Lucid Technologies,Henrietta,NY,美国)在新的原发性BCC的手术管理之前,将其作为诊断工具。方法这是一个前瞻性非劣效性多中心RCT,旨在将“使用RCM的OSS概念”与当前诊断和治疗临床可疑BCC的护理标准进行比较。 ≥18岁的患者在阿姆斯特丹大学学术医学中心皮肤科和荷兰癌症研究所-Antoni van Leeuwenhoek医院(荷兰阿姆斯特丹)皮肤科就诊,并被怀疑患有新的原发性BCC将使用预定义的纳入和排除标准考虑病变的纳入,并将其随机分配给实验组或对照组。主要结果参数是对已确认的BCC病变的最终病理报告(通过打孔活检或RCM成像)评估不完全的手术切除余量。其他结果指标包括用于诊断BCC并在亚型之间划分的RCM的诊断准确性(敏感性和特异性)以及吞吐时间。常规随访3个月后,将在术后收集患者满意度数据。结果本研究是由研究人员发起的,并获得了伦理学批准。患者招募始于2015年2月,我们预计所有与研究相关的活动将于2015年秋季完成。结论该RCT是第一个使用RCM检验OSS概念以诊断和治疗临床可疑BCC病变的方法。这项研究的结果有望在基于证据的实践中应用于越来越多的BCC病人,并可能导致更有效的疾病管理策略。试用注册ClinicalTrials.gov:NCT02285790; https://clinicaltrial.gov/ct2/show/NCT02285790(由WebCite存档,网址为http://www.webcitation.org/6b2LfDKWu)。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号